vs

Side-by-side financial comparison of ABERCROMBIE & FITCH CO (ANF) and Avantor, Inc. (AVTR). Click either name above to swap in a different company.

Avantor, Inc. is the larger business by last-quarter revenue ($1.7B vs $1.3B, roughly 1.3× ABERCROMBIE & FITCH CO). ABERCROMBIE & FITCH CO runs the higher net margin — 8.8% vs 3.1%, a 5.6% gap on every dollar of revenue. On growth, ABERCROMBIE & FITCH CO posted the faster year-over-year revenue change (6.8% vs -1.4%). ABERCROMBIE & FITCH CO produced more free cash flow last quarter ($131.8M vs $117.2M). Over the past eight quarters, Avantor, Inc.'s revenue compounded faster (-0.5% CAGR vs -5.8%).

Abercrombie & Fitch Co. (A&F) is an American lifestyle retailer founded in 1892, which focuses on contemporary clothing targeting customers in their early 20s to mid 40s. Headquartered in New Albany, Ohio, the company operates four offshoot brands: Abercrombie Kids, Your Personal Best, Hollister Co., and Gilly Hicks with 780+ company operated stores across its brands, as of Q4 2024.

Avantor, Inc. is an American biotechnology, chemicals, and pharmaceutical company headquartered in Radnor, Pennsylvania. Established in 1904 as J.T. Baker, the company changed its name to Avantor in 2010. Avantor went public in 2019 and is now listed on the New York Stock Exchange under the symbol “AVTR”.

ANF vs AVTR — Head-to-Head

Bigger by revenue
AVTR
AVTR
1.3× larger
AVTR
$1.7B
$1.3B
ANF
Growing faster (revenue YoY)
ANF
ANF
+8.1% gap
ANF
6.8%
-1.4%
AVTR
Higher net margin
ANF
ANF
5.6% more per $
ANF
8.8%
3.1%
AVTR
More free cash flow
ANF
ANF
$14.6M more FCF
ANF
$131.8M
$117.2M
AVTR
Faster 2-yr revenue CAGR
AVTR
AVTR
Annualised
AVTR
-0.5%
-5.8%
ANF

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
ANF
ANF
AVTR
AVTR
Revenue
$1.3B
$1.7B
Net Profit
$113.0M
$52.4M
Gross Margin
62.5%
31.5%
Operating Margin
12.0%
7.6%
Net Margin
8.8%
3.1%
Revenue YoY
6.8%
-1.4%
Net Profit YoY
-14.4%
-89.5%
EPS (diluted)
$2.36
$0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ANF
ANF
AVTR
AVTR
Q4 25
$1.3B
$1.7B
Q3 25
$1.2B
$1.6B
Q2 25
$1.1B
$1.7B
Q1 25
$1.6B
$1.6B
Q4 24
$1.2B
$1.7B
Q3 24
$1.1B
$1.7B
Q2 24
$1.0B
$1.7B
Q1 24
$1.5B
$1.7B
Net Profit
ANF
ANF
AVTR
AVTR
Q4 25
$113.0M
$52.4M
Q3 25
$141.4M
$-711.8M
Q2 25
$80.4M
$64.7M
Q1 25
$187.2M
$64.5M
Q4 24
$132.0M
$500.4M
Q3 24
$133.2M
$57.8M
Q2 24
$113.8M
$92.9M
Q1 24
$158.4M
$60.4M
Gross Margin
ANF
ANF
AVTR
AVTR
Q4 25
62.5%
31.5%
Q3 25
62.6%
32.4%
Q2 25
62.0%
32.9%
Q1 25
33.8%
Q4 24
65.1%
33.4%
Q3 24
64.9%
32.9%
Q2 24
66.4%
34.1%
Q1 24
62.9%
34.0%
Operating Margin
ANF
ANF
AVTR
AVTR
Q4 25
12.0%
7.6%
Q3 25
17.1%
-40.0%
Q2 25
9.3%
7.7%
Q1 25
16.2%
9.3%
Q4 24
14.8%
37.8%
Q3 24
15.5%
7.3%
Q2 24
12.7%
10.3%
Q1 24
15.3%
8.7%
Net Margin
ANF
ANF
AVTR
AVTR
Q4 25
8.8%
3.1%
Q3 25
11.7%
-43.8%
Q2 25
7.3%
3.8%
Q1 25
11.8%
4.1%
Q4 24
10.9%
29.7%
Q3 24
11.7%
3.4%
Q2 24
11.2%
5.5%
Q1 24
10.9%
3.6%
EPS (diluted)
ANF
ANF
AVTR
AVTR
Q4 25
$2.36
$0.08
Q3 25
$2.91
$-1.04
Q2 25
$1.59
$0.09
Q1 25
$3.55
$0.09
Q4 24
$2.50
$0.73
Q3 24
$2.50
$0.08
Q2 24
$2.14
$0.14
Q1 24
$2.97
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ANF
ANF
AVTR
AVTR
Cash + ST InvestmentsLiquidity on hand
$631.0M
$365.4M
Total DebtLower is stronger
$3.9B
Stockholders' EquityBook value
$1.3B
$5.6B
Total Assets
$3.5B
$11.8B
Debt / EquityLower = less leverage
0.71×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ANF
ANF
AVTR
AVTR
Q4 25
$631.0M
$365.4M
Q3 25
$603.5M
$251.9M
Q2 25
$607.6M
$449.4M
Q1 25
$888.9M
$315.7M
Q4 24
$738.9M
$261.9M
Q3 24
$738.4M
$285.3M
Q2 24
$864.2M
$272.6M
Q1 24
$900.9M
$234.9M
Total Debt
ANF
ANF
AVTR
AVTR
Q4 25
$3.9B
Q3 25
$3.9B
Q2 25
$4.2B
Q1 25
$4.1B
Q4 24
$4.1B
Q3 24
$4.9B
Q2 24
$5.1B
Q1 24
$5.3B
Stockholders' Equity
ANF
ANF
AVTR
AVTR
Q4 25
$1.3B
$5.6B
Q3 25
$1.3B
$5.6B
Q2 25
$1.2B
$6.3B
Q1 25
$1.3B
$6.1B
Q4 24
$1.2B
$6.0B
Q3 24
$1.2B
$5.6B
Q2 24
$1.1B
$5.4B
Q1 24
$1.0B
$5.3B
Total Assets
ANF
ANF
AVTR
AVTR
Q4 25
$3.5B
$11.8B
Q3 25
$3.3B
$11.7B
Q2 25
$3.1B
$12.8B
Q1 25
$3.3B
$12.3B
Q4 24
$3.3B
$12.1B
Q3 24
$3.0B
$12.8B
Q2 24
$3.0B
$12.7B
Q1 24
$3.0B
$12.8B
Debt / Equity
ANF
ANF
AVTR
AVTR
Q4 25
0.71×
Q3 25
0.69×
Q2 25
0.67×
Q1 25
0.67×
Q4 24
0.68×
Q3 24
0.89×
Q2 24
0.94×
Q1 24
1.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ANF
ANF
AVTR
AVTR
Operating Cash FlowLast quarter
$200.1M
$152.7M
Free Cash FlowOCF − Capex
$131.8M
$117.2M
FCF MarginFCF / Revenue
10.2%
7.0%
Capex IntensityCapex / Revenue
5.3%
2.1%
Cash ConversionOCF / Net Profit
1.77×
2.91×
TTM Free Cash FlowTrailing 4 quarters
$384.5M
$495.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ANF
ANF
AVTR
AVTR
Q4 25
$200.1M
$152.7M
Q3 25
$116.9M
$207.4M
Q2 25
$-4.0M
$154.4M
Q1 25
$307.6M
$109.3M
Q4 24
$142.6M
$173.3M
Q3 24
$165.1M
$244.8M
Q2 24
$95.0M
$281.1M
Q1 24
$303.3M
$141.6M
Free Cash Flow
ANF
ANF
AVTR
AVTR
Q4 25
$131.8M
$117.2M
Q3 25
$50.7M
$171.7M
Q2 25
$-54.8M
$124.8M
Q1 25
$256.8M
$81.3M
Q4 24
$92.2M
$145.8M
Q3 24
$122.3M
$204.0M
Q2 24
$56.1M
$235.3M
Q1 24
$274.1M
$106.9M
FCF Margin
ANF
ANF
AVTR
AVTR
Q4 25
10.2%
7.0%
Q3 25
4.2%
10.6%
Q2 25
-5.0%
7.4%
Q1 25
16.2%
5.1%
Q4 24
7.6%
8.6%
Q3 24
10.8%
11.9%
Q2 24
5.5%
13.8%
Q1 24
18.9%
6.4%
Capex Intensity
ANF
ANF
AVTR
AVTR
Q4 25
5.3%
2.1%
Q3 25
5.5%
2.2%
Q2 25
4.6%
1.8%
Q1 25
3.2%
1.8%
Q4 24
4.2%
1.6%
Q3 24
3.8%
2.4%
Q2 24
3.8%
2.7%
Q1 24
2.0%
2.1%
Cash Conversion
ANF
ANF
AVTR
AVTR
Q4 25
1.77×
2.91×
Q3 25
0.83×
Q2 25
-0.05×
2.39×
Q1 25
1.64×
1.69×
Q4 24
1.08×
0.35×
Q3 24
1.24×
4.24×
Q2 24
0.83×
3.03×
Q1 24
1.91×
2.34×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ANF
ANF

Hollister$673.3M52%
Abercrombie$617.3M48%
Gift Card$25.7M2%
Royalty$19.5M2%

AVTR
AVTR

Laboratory Solutions Segment$1.1B67%
Bioscience Production Segment$547.5M33%

Related Comparisons